Cend Therapeutics, Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Gets 5T4-Targeted NK Cell Therap

A Chinese stock exchange’s first-ever blunt refusal to a biotech’s initial public offering request has raised a red flag to some investors, who have been keeping a close watch on the in-licensing busi

The latest announcement regarding a tie-up between Qilu Pharmaceutical Co., Ltd. , a major Chinese active ingredient maker, and US biotech Sesen Bio, Inc. is aimed at accelerating the bladder cance

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genexine, KGBio Ink $1.1bn License Pact